UDP Glucuronosyltransferase (UGT) 1A6 Pharmacogenetics: I. Identification of Polymorphisms in the 5′-Regulatory and Exon 1 Regions, and Association with Human Liver UGT1A6 Gene Expression and Glucuronidation

  1. Soundararajan Krishnaswamy,
  2. Qin Hao,
  3. Abdul Al-Rohaimi,
  4. Leah M. Hesse,
  5. Lisa L. von Moltke,
  6. David J. Greenblatt and
  7. Michael H. Court
  1. Molecular Pharmacogenetics Laboratory (S.K., Q.H., A.A.-R., L.M.H., M.H.C.) and Clinical Pharmacology Laboratory (L.L.v.M., D.J.G.), Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Massachusetts
  1. Address correspondence to:
    Dr. Michael H. Court, Molecular Pharmacogenetics Laboratory, Department of Pharmacology and Experimental Therapeutics, Tufts University, 136 Harrison Ave., Boston, MA 02111. E-mail: michael.court{at}tufts.edu.

Abstract

UDP glucuronosyltransferase (UGT) 1A6 is a major isoform in human liver that glucuronidates numerous drugs, toxins, and endogenous substrates with high interindividual variability. The molecular basis for this variability remains unknown, although it likely involves genetic and environmental factors. Phenotype-genotype studies were conducted using a well characterized human liver bank (n = 54) and serotonin glucuronidation as a UGT1A6-specific phenotype marker. A positive moderate-to-heavy alcohol use history (>14 drinks per week) was the only demographic factor examined that correlated with phenotype and was associated with 2-fold higher serotonin glucuronidation (p < 0.001), UGT1A6 protein content (p = 0.004), and UGT1A6 mRNA content (p = 0.025). UGT1A6 gene resequencing identified three nonsynonymous polymorphisms (S7A, T181A, and R184S) in exon 1 and eight novel polymorphisms in the 5′-regulatory region (to -2052 base pairs). S7A was in complete linkage disequilibrium with three 5′-regulatory region polymorphisms (-1710c→g, -1310del5, and -652g→a). Initial univariate analyses did not identify any significant phenotype-genotype associations. However, in livers without substantial alcohol exposure, 50% lower UGT1A6 mRNA levels (p = 0.026) were found in carriers of the linked S7A-enhancer polymorphisms compared with noncarriers but without significant effect on UGT1A6 protein content or glucuronidation activities. Three major haplotypes, including *1A (reference), *1B (-1535g→a and -427g→c), and *2 (-1710c→g, -1310del5, -652g→a, S7A, T181A, and R184S), were identified, accounting for 90% of alleles. No association of haplotype with any of the phenotype measures could be discerned. In conclusion, although the identified UGT1A6 polymorphisms did not explain the observed glucuronidation variability, there does seem to be a significant role for environmental factors associated with alcohol consumption.

Footnotes

  • This work was supported by Grants GM-61834, DA-05258, MH-58435, DA-13209, DK-58496, AG-17880, AT-01381, AI-058784, and RR-00054 from the National Institutes of Health and by Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development (Ann Arbor, MI).

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.104.081950.

  • ABBREVIATIONS: UGT, UDP glucuronosyltransferase; bp, base pair(s); HLM, human liver microsome; PCR, polymerase chain reaction; SNP, single nucleotide polymorphism; PXR, pregnane X receptor; CAR, constitutive androstane receptor; ANOVA, analysis of variance; cSNP, coding single nucleotide polymorphism.

    • Received December 7, 2004.
    • Accepted March 3, 2005.
« Previous | Next Article »Table of Contents